دورية أكاديمية
أعرض في EDS

CD73 as a target to improve temozolomide chemotherapy effect in glioblastoma preclinical model.

التفاصيل البيبلوغرافية
العنوان: CD73 as a target to improve temozolomide chemotherapy effect in glioblastoma preclinical model.
المؤلفون: Azambuja JH; Programa de Pós-Graduação Em Biociências, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Rua Sarmento Leite, 245-Prédio Principal, Porto Alegre, RS, 90050-170, Brazil. julianahazambuja@hotmail.com., Schuh RS; Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil., Michels LR; Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil., Gelsleichter NE; Programa de Pós-Graduação Em Biociências, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Rua Sarmento Leite, 245-Prédio Principal, Porto Alegre, RS, 90050-170, Brazil., Beckenkamp LR; Programa de Pós-Graduação Em Biociências, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Rua Sarmento Leite, 245-Prédio Principal, Porto Alegre, RS, 90050-170, Brazil., Lenz GS; Programa de Pós-Graduação Em Biociências, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Rua Sarmento Leite, 245-Prédio Principal, Porto Alegre, RS, 90050-170, Brazil., de Oliveira FH; Departamento de Patologia, UFRGS, Porto Alegre, RS, Brazil., Wink MR; Programa de Pós-Graduação Em Biociências, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Rua Sarmento Leite, 245-Prédio Principal, Porto Alegre, RS, 90050-170, Brazil., Stefani MA; Departamento de Morfologia, UFRGS, Porto Alegre, RS, Brazil., Battastini AMO; Departamento de Bioquímica, UFRGS, Porto Alegre, RS, Brazil., Teixeira HF; Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil., Braganhol E; Programa de Pós-Graduação Em Biociências, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Rua Sarmento Leite, 245-Prédio Principal, Porto Alegre, RS, 90050-170, Brazil.
المصدر: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2020 Jun; Vol. 85 (6), pp. 1177-1182. Date of Electronic Publication: 2020 May 16.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0843 (Electronic) Linking ISSN: 03445704 NLM ISO Abbreviation: Cancer Chemother Pharmacol Subsets: MEDLINE
أسماء مطبوعة: Publication: Berlin : Springer Verlag
Original Publication: Berlin, New York, Springer International.
مواضيع طبية MeSH: 5'-Nucleotidase/*antagonists & inhibitors , Brain Neoplasms/*drug therapy , Drug Resistance, Neoplasm/*genetics , Glioblastoma/*drug therapy , RNA, Small Interfering/*genetics , Temozolomide/*pharmacology, 5'-Nucleotidase/genetics ; Animals ; Antineoplastic Agents, Alkylating/pharmacology ; Apoptosis ; Brain Neoplasms/genetics ; Brain Neoplasms/pathology ; Cell Proliferation ; Drug Evaluation, Preclinical ; Glioblastoma/genetics ; Glioblastoma/pathology ; Humans ; Male ; RNA, Small Interfering/administration & dosage ; Rats ; Rats, Wistar ; Tumor Cells, Cultured ; Xenograft Model Antitumor Assays
مستخلص: Glioblastoma is the most devastating primary brain tumor and effective therapies are not available. Treatment is based on surgery followed by radio and chemotherapy with temozolomide (TMZ), but TMZ increases patient survival only by 2 months. CD73, an enzyme responsible for adenosine production, emerges as a target for glioblastoma treatment. Indeed, adenosine causes tumor-promoting actions and CD73 inhibition increases sensitivity to TMZ in vitro. Here, a cationic nanoemulsion to nasal delivery of siRNA CD73 (NE-siRNA CD73) aiming glioblastoma treatment was employed alone or in combination with TMZ. In vitro, two glioblastoma cell lines (C6 and U138MG) with a chemo-resistant profile were used. Treatment alone with NE-siRNA CD73 reduced C6 and U138MG glioma cell viability by 70% and 25%, respectively. On the other hand, when NE-siRNA + TMZ combined treatment was employed, a reduction of 85% and 33% of cell viability was observed. Notably, treatment with NE-siRNA CD73 of glioma-bearing Wistar rats reduced tumor size by 80%, 60% more than the standard chemotherapy with TMZ, but no synergistic or additive effect was observed in vivo. Additionally, NE-siRNA CD73, TMZ or combined therapy decreased adenosine levels in liquor confirming the importance of this nucleoside on in vivo GB growth. Finally, no hemolytic potential was observed. These results suggest that nasal administration of NE-siRNA CD73 exhibits higher antiglioma effect when compared to TMZ. However, no synergistic or additive in vivo was promoted by the therapeutic regimen employed in this study.
References: Ostrom QT, Bauchet L, Davis FG et al (2014) The epidemiology of glioma in adults: a "state of the science" review. Neuro Oncol 16:896–913. https://doi.org/10.1093/neuonc/nou087. (PMID: 10.1093/neuonc/nou087248429564057143)
Chua J, Nafziger E, Leung D (2019) Evidence-based practice: temozolomide beyond glioblastoma. Curr Oncol Rep 21:1–9. https://doi.org/10.1007/s11912-019-0783-5. (PMID: 10.1007/s11912-019-0783-5)
Stupp R, van den Bent MJ, Hegi ME (2005) Optimal role of temozolomide in the treatment of malignant gliomas. Curr Neurol Neurosci Rep 5:198–206. (PMID: 10.1007/s11910-005-0047-7)
Wijaya J, Fukuda Y, Schuetz JD (2017) Obstacles to brain tumor therapy: key ABC transporters. Int J Mol Sci. https://doi.org/10.3390/ijms18122544. (PMID: 10.3390/ijms18122544291868995751147)
Azambuja JH, Gelsleichter NE, Beckenkamp LR et al (2018) CD73 downregulation decreases In vitro and In vivo glioblastoma growth. Mol Neurobiol. https://doi.org/10.1007/s12035-018-1240-4. (PMID: 10.1007/s12035-018-1240-430117104)
Quezada C, Garrido W, Oyarzún C et al (2013) 5’-ectonucleotidase mediates multiple-drug resistance in glioblastoma multiforme cells. J Cell Physiol 228:602–608. https://doi.org/10.1002/jcp.24168. (PMID: 10.1002/jcp.2416822833450)
Bavaresco L, Bernardi A, Braganhol E et al (2008) The role of ecto-5′-nucleotidase/CD73 in glioma cell line proliferation. Mol Cell Biochem 319:61–68. https://doi.org/10.1007/s11010-008-9877-3. (PMID: 10.1007/s11010-008-9877-318636315)
Azambuja JH, Schuh RS, Michels LR et al (2019) Nasal administration of cationic nanoemulsions as CD73-siRNA delivery system for glioblastoma treatment : a new therapeutical approach. Mol Neurobiol 57:635–649. (PMID: 10.1007/s12035-019-01730-6)
Gehrcke M, Giuliani LM, Ferreira LM et al (2017) Enhanced photostability, radical scavenging and antitumor activity of indole-3-carbinol-loaded rose hip oil nanocapsules. Mater Sci Eng C. https://doi.org/10.1016/j.msec.2016.12.006. (PMID: 10.1016/j.msec.2016.12.006)
Da Silveira EF, Chassot JM, Teixeira FC et al (2013) Ketoprofen-loaded polymeric nanocapsules selectively inhibit cancer cell growth in vitro and in preclinical model of glioblastoma multiforme. Invest New Drugs 31:1424–1435. https://doi.org/10.1007/s10637-013-0016-y. (PMID: 10.1007/s10637-013-0016-y24072435)
da Silveira EF, Azambuja JH, de Carvalho TR et al (2017) Synthetic 2-aryl-3-((piperidin-1-yl)ethyl)thiazolidin-4-ones exhibit selective in vitro antitumoral activity and inhibit cancer cell growth in a preclinical model of glioblastoma multiforme. Chem Biol Interact 266:1–9. https://doi.org/10.1016/j.cbi.2017.02.001. (PMID: 10.1016/j.cbi.2017.02.00128174097)
Torres A, Vargas Y, Uribe D et al (2016) Adenosine A 3 receptor elicits chemoresistance mediated by multiple resistance-associated protein-1 in human glioblastoma stem-like cells. Oncotarget 7:67373–67386. https://doi.org/10.18632/oncotarget.12033. (PMID: 10.18632/oncotarget.12033276349135341882)
Azambuja JH, Ludwig N, Braganhol E, Whiteside TL (2019) Inhibition of the adenosinergic pathway in cancer rejuvenates innate and adaptive immunity. Int J Mol Sci 20:5698. https://doi.org/10.3390/ijms20225698. (PMID: 10.3390/ijms202256986888217)
Wink MR, Lenz G, Braganhol E et al (2003) Altered extracellular ATP, ADP and AMP catabolism in glioma cell lines. Cancer Lett 198:211–218. https://doi.org/10.1016/S0304-3835(03)00308-2. (PMID: 10.1016/S0304-3835(03)00308-212957360)
فهرسة مساهمة: Keywords: Adenosine; CD73; Glioma; Nanoemulsion; Temozolomide
المشرفين على المادة: 0 (Antineoplastic Agents, Alkylating)
0 (RNA, Small Interfering)
EC 3.1.3.5 (5'-Nucleotidase)
YF1K15M17Y (Temozolomide)
تواريخ الأحداث: Date Created: 20200518 Date Completed: 20210215 Latest Revision: 20210720
رمز التحديث: 20221213
DOI: 10.1007/s00280-020-04077-1
PMID: 32417936
قاعدة البيانات: MEDLINE
الوصف
تدمد:1432-0843
DOI:10.1007/s00280-020-04077-1